Form 4: Precision BioSciences Director Equity Vesting

Director Kevin Buehler acquired 21,000 shares of Precision BioSciences common stock following the vesting of restricted stock units.

Summary

• Director Kevin Buehler acquired 21,000 shares of common stock on May 20, 2026.
• The acquisition resulted from the vesting of previously granted restricted stock units (RSUs).
• Following this transaction, the director holds a total of 49,137 shares of common stock.
• The transaction was executed at a zero-cost basis as part of an equity compensation plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard equity compensation vesting with no impact on company operations.

Positives

• Director maintains a significant equity stake in the company, aligning interests with shareholders.
• The transaction reflects the fulfillment of standard equity compensation vesting schedules.

Negatives

• None identified; this is a routine administrative filing regarding equity compensation.

Risks

• None identified; this filing relates to internal equity compensation rather than operational or market risks.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that routine equity vesting for directors is standard practice in the biotechnology sector to ensure long-term alignment between board members and corporate performance.

Comparison to Industry Standards

• The transaction follows standard corporate governance practices for equity-based compensation in the biotech industry.
• The vesting schedule is consistent with typical director compensation packages for small-cap life sciences companies.

Stakeholder Impact

• Minimal impact on shareholders as this represents the fulfillment of existing compensation agreements.

Next Steps

• None identified.

Key Dates

Keywords

Precision BioSciences, DTIL, Form 4, Insider Trading, Equity Compensation, Director Ownership